ReviewJournal of experimental & clinical cancer research : CR2009
Chromophobe renal cell cancer--review of the literature and potential methods of treating metastatic disease.
Review in Journal of experimental & clinical cancer research : CR, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 67 citations in OpenAlex.
- Does chromophobe renal cell carcinoma have better survival than clear cell renal cell carcinoma? A clinical-based cohort study and meta-analysis.International urology and nephrology · 2016Pooled it
- Trial
- Development and Validation of a Competitive Risk Model in Elderly Patients With Chromophobe Cell Renal Carcinoma: A Population-Based Study.Frontiers in public health · 2022Trial
- Article
- Durable disease control with cabozantinib in metastatic chromophobe renal cell carcinoma: A rare case with promising outcomes.Urology case reports · 2025Article
- Late solitary metastasis of chromophobe renal cell carcinoma in the residual ureter.IJU case reports · 2025Article
- Grading Challenges and Prognostic Insights in Chromophobe Renal Cell Carcinoma: A Retrospective Study of 72 Patients.Medicina (Kaunas, Lithuania) · 2024Article
- Intravesical recurrence of chromophobe renal cell carcinoma.Urology case reports · 2023Article
- The prognostic role of cigarette smoking in Kidney Cancer Survival.Cancer medicine · 2023Article
- Review
- Article
- A CT-based radiomics nomogram for differentiation of renal oncocytoma and chromophobe renal cell carcinoma with a central scar-matched study.The British journal of radiology · 2022Article
- Kidney re-transplantation after living donor graft nephrectomy due toWorld journal of clinical cases · 2021Article
- Genomic profiling in renal cell carcinoma.Nature reviews. Nephrology · 2020Review
- Selected tumor markers in the routine diagnosis of chromophobe renal cell carcinoma.Archives of medical science : AMS · 2016Article
- Comparison of computed tomography findings between renal oncocytomas and chromophobe renal cell carcinomas.Korean journal of urology · 2015Article
- BSND and ATP6V1G3: Novel Immunohistochemical Markers for Chromophobe Renal Cell Carcinoma.Medicine · 2015Article
- Monocyte-derived dendritic cells reflect the immune functional status of a chromophobe renal cell carcinoma patient: could it be a general phenomenon?Cancer immunology, immunotherapy : CII · 2015Article
- Mapping of carboxypeptidase m in normal human kidney and renal cell carcinoma: expression in tumor-associated neovasculature and macrophages.The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society · 2013Article
- LMP2, a novel immunohistochemical marker to distinguish renal oncocytoma from the eosinophilic variant of chromophobe renal cell carcinoma.Experimental and molecular pathology · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chromophobe renal cell carcinoma (ChRCC) is a subtype of renal cell carcinoma (RCC). ChRCC is diagnosed mainly in 6th decade of life. An incidence of ChRCC is similar in both men and woman. Eighty six percent of ChRCCs cases are diagnosed in stage 1 or 2. Prognosis of ChRCC is better than in other types of RCC. Five- and 10-year disease free survival (DFS) for ChRCC was 83.9% and 77.9%, respectively. Expression of immunohistological markers: cytokeratins (CK), vimentin, epithelial membrane antigen (EMA), CD10 could be potentially helpful in diagnosis of different subtypes of RCC. From all conventional RCC, CD 117 was detected (overexpression) in membrane of cells ChRCC.Overexpression of CD117 on cellular membranes of ChRCC could be a potential target for kinase inhibitors like: imatinib, dasatinib, nilotinib. The potential targets for other kinase inhibitors (sunitinib and sorafenib) in ChRCC seem to be VEGFR and PDGFR. On the basis for formulating research hypotheses which should be verified by prospective studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.